Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,100 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 4,100 shares of the stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $12.62 per share, for a total transaction of $51,742.00. Following the completion of the transaction, the chief executive officer directly owned 5,592,202 shares of the company’s stock, valued at $70,573,589.24. This trade represents a 0.07% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $8.37 per share, with a total value of $38,502.00.
• On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Stock Performance

Shares of GLSI stock opened at $12.39 on Friday. The stock has a market cap of $171.66 million, a PE ratio of -8.49 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 1 year low of $7.78 and a 1 year high of $14.47. The stock has a fifty day moving average price of $9.17 and a 200 day moving average price of $10.23.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.30). As a group, equities research analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its holdings in Greenwich LifeSciences by 52.1% in the 3rd quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after purchasing an additional 7,174 shares in the last quarter. Vanguard Group Inc. boosted its position in Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after acquiring an additional 13,179 shares during the last quarter. Marshall Wace LLP purchased a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $509,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at $25,000. Finally, Geode Capital Management LLC lifted its stake in shares of Greenwich LifeSciences by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock worth $1,261,000 after purchasing an additional 1,972 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Greenwich LifeSciences in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $42.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.